CORAL GABLES, Fla., March 8, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has agreed to sell 2,259,943 shares of its common stock at a price of $1.12 per share, the closing price on March 7, 2011, in a firm commitment underwritten public offering. Catalyst expects to receive net proceeds, after underwriting discounts and commissions and estimated offering expenses payable by the Company, of approximately $2.2 million. Catalyst expects to use the net proceeds from this offering to complete the non-clinical studies necessary to file an Investigational New Drug Application with the FDA for CPP-115, to fund a Phase I human clinical trial of CPP-115 and for general corporate purposes.
Catalyst Pharmaceutical Partners, Inc. Announces Public Offering Of Common Shares
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.